Want to see TSE:AVCN full AI Analyst Report?
Top Page
Avicanna
(TSX:AVCN)
Select Model
Select Model
Rating:41Neutral
Price Target:
C$0.10
▼(-23.08% Downside)
Action:Reiterated
Date:09/09/26
The score is primarily constrained by weak financial performance driven by persistent losses and ongoing negative operating/free cash flow, despite improved margins and a more manageable leverage profile. Technicals add further pressure, with the stock in a clear downtrend and negative momentum. Valuation provides limited offset because the company is loss-making (negative P/E) and does not offer dividend support.
Positive Factors
Gross Margin
Gross margins above 50% in 2024–TTM show that Avicanna’s products retain meaningful economics after direct costs. This provides a stronger foundation for future operating improvement, although the company still needs sufficient scale and cost discipline to convert that margin into profit.
Negative Factors
Persistent Cash Burn
Negative operating and free cash flow across every reported period means the business has not yet funded itself through operations. Continued cash burn can constrain investment and increase reliance on external financing, making sustained cash break-even a central requirement for stability.
Read all positive and negative factors
Positive Factors
Negative Factors
Gross Margin
Gross margins above 50% in 2024–TTM show that Avicanna’s products retain meaningful economics after direct costs. This provides a stronger foundation for future operating improvement, although the company still needs sufficient scale and cost discipline to convert that margin into profit.
Read all positive factors
Avicanna (AVCN) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$17.47M
Dividend YieldN/A
Average Volume (3M)48.63K
Price to Earnings (P/E)―
Beta (1Y)1.07
Revenue Growth-0.23%
EPS Growth-142.54%
CountryCA
Employees112
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.03
Shares Outstanding134,383,850
10 Day Avg. Volume53,094
30 Day Avg. Volume48,635
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)9.08
Price to Sales (P/S)1.01
P/FCF Ratio-17.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Avicanna Business Overview & Revenue Model
Company Description
Avicanna Inc., a biopharmaceutical firm headquartered in Toronto, Canada, and founded in 2016, is actively engaged in the research, development, and commercialization of scientifically validated products for both global medical and consumer health...
How the Company Makes Money
Avicanna makes money primarily by selling cannabinoid-based products and related services through regulated medical and pharmaceutical channels. Key revenue streams include: (1) Product sales: revenue from finished, formulated cannabis/cannabinoid...
Avicanna Earnings Call Summary
Earnings Call Date:Apr 01, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Nov 12, 2026
Earnings Call Sentiment Positive
The call emphasized material operational and scientific progress—improved gross margins (53%, +10 pts), reduced operating expenses (–9%), stronger liquidity (working capital +23%), R&D/IP milestones (PwdRX/data and new USPTO patent), and clinical advancements (450 patient RWE study published; Phase II underway). These positives were tempered by flat top-line revenue at $25.5M, a still-negative full-year adjusted EBITDA (–$300k) and net loss ($2.7M), early-stage commercial launches (soft launch of Trunerox) and ongoing regulatory and market uncertainties (U.S. rescheduling dependency and stock overhang). On balance, the company presented clear momentum on margins, efficiency, IP and clinical programs while acknowledging remaining commercialization and market-risk headwinds.Positive Updates
Stable Revenue with Improved Profitability
Total revenue of $25.5M in 2025, essentially flat year-over-year, accompanied by improved profitability metrics: gross profit of $13.5M and a gross margin of 53% (up 10 percentage points from 48% in 2024).
Negative Updates
Top-Line Growth Was Modest / Flat
Revenue remained flat at $25.5M year-over-year, indicating limited top-line growth despite other operational improvements.
Read all updates
Q4-2025 Updates
Positive
Negative
Stable Revenue with Improved Profitability
Total revenue of $25.5M in 2025, essentially flat year-over-year, accompanied by improved profitability metrics: gross profit of $13.5M and a gross margin of 53% (up 10 percentage points from 48% in 2024).
Read all positive updates
Company Guidance
Guidance for 2026 targets continued profitable, capital-light scaling: management plans to internationalize RHO Phyto and roll out 3.0 fast-acting products while leveraging two new delivery platforms finalized in 2025 (in fluid and PwdRX — PwdRX showed a 74% increase in bioavailability, 63% higher peak plasma concentration and 134% higher peak concentration versus MCT oil in vitro). Key numeric goals and context: 2025 revenue was $25.5M (MyMedi $20.4M), gross profit $13.5M (53% margin, +10% vs 2024), adjusted EBITDA loss improved to $300k (71% improvement vs a $1.0M loss in 2024) with Q4 adjusted EBITDA positive $310k, net loss down 41% to $2.7M, working capital +23%, only $1.0M raised in 2025 (vs $4.8M in 2024), no debt, 50 Canadian SKUs with 170 listings ( listings +26% YoY), presence in 24 markets and a planned Australia launch (6th continent), continued RWE (≈450 patients) and active Phase I/II trials, plus scaling exports from Aureus (international revenue ~$1.9M) and pursuit of a U.S. senior-exchange listing.Avicanna Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
52
Neutral
Cash Flow
34
Negative
| Breakdown | TTM | Mar 2026 | Dec 2024 | Mar 2024 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 25.31M | 25.48M | 25.46M | 16.79M | 4.05M | 3.27M |
| Gross Profit | 13.13M | 12.84M | 12.90M | 6.66M | 1.11M | 2.83M |
| EBITDA | -3.04M | -1.97M | -2.43M | -7.36M | -12.18M | -15.13M |
| Net Income | -3.91M | -2.84M | -3.62M | -8.74M | -14.73M | -16.77M |
Balance Sheet | ||||||
| Total Assets | 24.13M | 21.24M | 20.12M | 21.97M | 17.62M | 22.30M |
| Cash, Cash Equivalents and Short-Term Investments | 200.42K | 280.63K | 448.03K | 477.20K | 1.19M | 31.00K |
| Total Debt | 169.56K | 0.00 | 109.23K | 1.80M | 3.21M | 1.66M |
| Total Liabilities | 10.12M | 9.86M | 10.38M | 14.00M | 14.16M | 15.39M |
| Stockholders Equity | 4.60M | 2.84M | 2.31M | -112.50K | -383.56K | 1.15M |
Cash Flow | ||||||
| Free Cash Flow | -3.36M | -1.44M | -2.95M | -1.96M | -7.50M | -12.45M |
| Operating Cash Flow | -3.15M | -1.18M | -2.55M | -1.40M | -7.44M | -11.66M |
| Investing Cash Flow | -207.88K | -255.84K | -402.57K | -3.05M | 810.24K | 760.83K |
| Financing Cash Flow | 3.20M | 963.17K | 3.41M | 3.55M | 9.90M | 10.06M |
Avicanna Technical Analysis
Negative
0.13
Price Trends
0.13
Negative
0.13
Negative
0.16
Negative
Market Momentum
>-0.01
Positive
36.27
Neutral
26.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AVCN, the sentiment is Negative. The current price of 0.13 is above the 20-day moving average (MA) of 0.13, above the 50-day MA of 0.13, and below the 200-day MA of 0.16, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 36.27 is Neutral, neither overbought nor oversold. The STOCH value of 26.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:AVCN.
Avicanna Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | C$32.04M | -6.47 | -13.79% | ― | -6.74% | 43.54% | |
53 Neutral | C$356.31M | -8.89 | -180.13% | ― | ― | 29.34% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | C$119.37M | -1.55 | -285.09% | ― | -7.77% | -52.56% | |
44 Neutral | C$10.35M | -8.22 | -19.37% | ― | -19.20% | 42.54% | |
41 Neutral | C$17.47M | -3.24 | -108.44% | ― | -0.23% | -142.54% | |
41 Neutral | C$11.21M | -2.94 | 28.59% | ― | 0.90% | 57.73% |
* Healthcare Sector Average
TSE:AVCN
Avicanna
0.11
-0.16
-59.26%
TSE:CWEB
Charlotte's Web Holdings
0.47
0.32
220.69%
TSE:LABS
MediPharm Labs
0.08
<0.01
7.14%
TSE:PCLO
PharmaCielo
0.07
0.02
44.44%
TSE:CRDL
Cardiol Therapeutics
3.16
1.66
110.67%
TSE:INNO
InnoCan Pharma
2.00
-10.34
-83.79%
Avicanna Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Avicanna Secures Strategic Private Placement Led by Pharma Investor Michael Porter
Positive
Aug 19, 2026
Avicanna Inc., a biopharmaceutical company focused on plant-derived cannabinoid-based products for global medical and pharmaceutical markets, has built a diversified platform spanning branded medical cannabis, a patient-centric care portal, clinic...
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
Avicanna Lifts Margins and Expands Portfolio Ahead of QUIX Launch Despite VAC Headwinds
Positive
Aug 14, 2026
Avicanna reported Q2 2026 revenue of $5.64 million, down 8% year over year, as reduced Veterans Affairs Canada reimbursement rates and timing of certain business unit revenues weighed on sales. Despite this, proprietary product volumes rose 33% ye...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.